Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling

• Published in: Cancers Vol. 15; no. 2; p. 460
• Main Authors: Cecchi, Fabiola, Rex, Karen, Schmidt, Joanna, Vocke, Cathy D, Lee, Young H, Burkett, Sandra, Baker, Daniel, Damore, Michael A, Coxon, Angela, Burgess, Teresa L, Bottaro, Donald P
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 11-01-2023; MDPI
• Subjects: Antibodies; Autocrine signalling; Biosynthesis; Brain cancer; c-Met protein; Cancer; Cell activation; Cell survival; Cells; Cholesterol; Clinical trials; Disease control; Drug development; Drug resistance; Endoplasmic reticulum; Experiments; Glioblastoma; Glioblastoma cells; Growth factors; Hepatocyte growth factor; Immunoassay; Kinases; Laboratory animals; Proteins; Regression analysis; Signal transduction; Tumors; United States > US; Thousand Oaks California; glioblastoma; rilotumumab; acquired drug resistance; Met; hepatocyte growth factor
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15020460

Drug resistance is a long-standing impediment to effective systemic cancer therapy and acquired drug resistance is a growing problem for molecularly-targeted therapeutics that otherwise have shown unprecedented successes in disease control. The hepatocyte growth factor (HGF)/Met receptor pathway signaling is frequently involved in cancer and has been a subject of targeted drug development for nearly 30 years. To anticipate and study specific resistance mechanisms associated with targeting this pathway, we engineered resistance to the HGF-neutralizing antibody rilotumumab in glioblastoma cells harboring autocrine HGF/Met signaling, a frequent abnormality of this brain cancer in humans. We found that rilotumumab resistance was acquired through an unusual mechanism comprising dramatic HGF overproduction and misfolding, endoplasmic reticulum (ER) stress-response signaling and redirected vesicular trafficking that effectively sequestered rilotumumab and misfolded HGF from native HGF and activated Met. Amplification of
and
genes, with evidence of rapidly acquired intron-less, reverse-transcribed copies in DNA, was also observed. These changes enabled persistent Met pathway activation and improved cell survival under stress conditions. Point mutations in the HGF pathway or other complementary or downstream growth regulatory cascades that are frequently associated with targeted drug resistance in other prevalent cancer types were not observed. Although resistant cells were significantly more malignant, they retained sensitivity to Met kinase inhibition and acquired sensitivity to inhibition of ER stress signaling and cholesterol biosynthesis. Defining this mechanism reveals details of a rapidly acquired yet highly-orchestrated multisystem route of resistance to a selective molecularly-targeted agent and suggests strategies for early detection and effective intervention.